{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:51:43Z","timestamp":1781769103146,"version":"3.54.5"},"reference-count":266,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Gynecological tumors are a group of prevalent and highly lethal malignancies affecting the female reproductive system. The immunosuppressive tumor microenvironment, characterized by immune cell dysfunction and inhibitory cytokine dysregulation, plays a pivotal role in tumor initiation, progression, and resistance to conventional therapies. Although standard treatments\u2014including surgery, radiotherapy, and chemotherapy\u2014remain the mainstay for early-stage disease, they often fail to manage advanced, recurrent, or drug-resistant tumors. In recent years, immunotherapy has emerged as a transformative approach in cancer treatment, offering new hope for patients with gynecological malignancies. Notably, immune checkpoint inhibitors, adoptive cell therapy, and cancer therapeutic vaccines have exhibited encouraging efficacy across several clinical trials. This review systematically summarizes recent advances in immunotherapy for major gynecological cancers, including cervical cancer, endometrial cancer, and ovarian cancer. We focus on the immunological landscape of these tumors, the underlying mechanisms of immune-based therapies, key clinical findings, and current challenges. In addition, we highlight future research directions and explore prospects for personalized immunotherapy, aiming to provide both theoretical insight and practical guidance for clinical translation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000004166","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:00:10Z","timestamp":1781766010000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy for gynecological tumors: From mechanism to clinical practice"],"prefix":"10.1097","author":[{"given":"Jian","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, Women\u2019s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China"},{"name":"Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women\u2019s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Women\u2019s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China"},{"name":"Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women\u2019s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Women\u2019s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China"},{"name":"Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women\u2019s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"R1-20260618","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260618","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"R3-20260618","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","article-title":"Cervical cancer","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"R4-20260618","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ijgc-2022-003675","article-title":"Immunotherapy in endometrial cancer","volume":"33","author":"Mahdi","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"R5-20260618","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.029","article-title":"Immunotherapy for gynecologic cancers","volume":"142","author":"Liao","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R6-20260618","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.3390\/cancers13092089","article-title":"Role of immune checkpoint inhibitors in cervical cancer: From preclinical to clinical data","volume":"13","author":"Duranti","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R7-20260618","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ygyno.2024.01.032","article-title":"The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations","volume":"184","author":"Santoro","year":"2024","journal-title":"Gynecol Oncol"},{"key":"R8-20260618","first-page":"941","article-title":"TIME is ticking for cervical cancer","volume":"12","author":"Kumar","year":"2023","journal-title":"Biology (Basel)"},{"key":"R9-20260618","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.3390\/ijms21093125","article-title":"The ovarian cancer tumor immune microenvironment (TIME) as target for therapy: A focus on innate immunity cells as therapeutic effectors","volume":"21","author":"Baci","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R10-20260618","article-title":"Tumor microenvironment promotes lymphatic metastasis of cervical cancer: its mechanisms and clinical implications","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"},{"key":"R11-20260618","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1186\/s12885-025-13901-x","article-title":"Single-cell transcriptomic analysis reveals CD8+\u2009T cell heterogeneity and identifies a prognostic signature in cervical cancer","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Cancer"},{"key":"R12-20260618","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116498","article-title":"Gynecological cancer tumor microenvironment: Unveiling cellular complexity and therapeutic potential","volume":"229","author":"Garg","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"R13-20260618","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.3390\/ijms23105756","article-title":"The role of microbiota in the immunopathogenesis of endometrial cancer","volume":"23","author":"Sobstyl","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R14-20260618","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103675","article-title":"Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies","volume":"174","author":"Bhattacharjee","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"R15-20260618","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3390\/v16030327","article-title":"HPV and cervical cancer: Molecular and immunological aspects, epidemiology and effect of vaccination in Latin American women","volume":"16","author":"Hern\u00e1ndez-Silva","year":"2024","journal-title":"Viruses"},{"key":"R16-20260618","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/2159-8290.CD-20-1760","article-title":"Tumor immunity and immunotherapy for HPV-related cancers","volume":"11","author":"Shamseddine","year":"2021","journal-title":"Cancer Discov"},{"key":"R17-20260618","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1038\/s41467-022-33982-7","article-title":"Single-cell transcriptomic analysis highlights origin and pathological process of human endometrioid endometrial carcinoma","volume":"13","author":"Ren","year":"2022","journal-title":"Nat Commun"},{"key":"R18-20260618","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108526","article-title":"The role and participation of immune cells in the endometrial tumor microenvironment","volume":"251","author":"Dey","year":"2023","journal-title":"Pharmacol Ther"},{"key":"R19-20260618","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41419-024-06960-8","article-title":"Single-cell transcriptome profiles the heterogeneity of tumor cells and microenvironments for different pathological endometrial cancer and identifies specific sensitive drugs","volume":"15","author":"Ren","year":"2024","journal-title":"Cell Death Dis"},{"key":"R20-20260618","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115987","article-title":"Developments in genetics: Better management of ovarian cancer patients","volume":"24","author":"Maioru","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R21-20260618","doi-asserted-by":"crossref","first-page":"x16","DOI":"10.1093\/annonc\/mdt463","article-title":"Origin and molecular pathogenesis of ovarian high-grade serous carcinoma","volume":"24","author":"Kurman","year":"2013","journal-title":"Ann Oncol"},{"key":"R22-20260618","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"R23-20260618","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.it.2024.12.006","article-title":"Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments","volume":"46","author":"Gupta","year":"2025","journal-title":"Trends Immunol"},{"key":"R24-20260618","article-title":"Features of the immunosuppressive tumor microenvironment in endometrial cancer based on molecular subtype","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"R25-20260618","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.omto.2021.07.006","article-title":"Prognostic and therapeutic TILs of cervical cancer: Current advances and future perspectives","volume":"22","author":"Tang","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"R26-20260618","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/0008-5472.CAN-06-3388","article-title":"High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer","volume":"67","author":"Piersma","year":"2007","journal-title":"Cancer Res"},{"key":"R27-20260618","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1158\/1078-0432.CCR-0732-3","article-title":"Intratumoral CD8+T lymphocytes as a prognostic factor of survival in endometrial carcinoma","volume":"10","author":"Kondratiev","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R28-20260618","article-title":"Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer","volume":"3","author":"Goode","year":"2017","journal-title":"JAMA Oncol"},{"key":"R29-20260618","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s11864-021-00929-x","article-title":"Natural killer cells: the missing link in effective treatment for high-grade serous ovarian carcinoma","volume":"23","author":"Pugh-Toole","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"R30-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008355","article-title":"Multiomics profiling reveals the benefits of gamma-delta (gammadelta) T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer","volume":"12","author":"Li","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R31-20260618","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022110757","article-title":"Single\u2010cell dissection of cervical cancer reveals key subsets of the tumor immune microenvironment","volume":"42","author":"Cao","year":"2023","journal-title":"EMBO J"},{"key":"R32-20260618","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12964-024-01834-0","article-title":"BTN3A1 expressed in cervical cancer cells promotes V\u03b39V\u03b42 T cells exhaustion through upregulating transcription factors NR4A2\/3 downstream of TCR signaling","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun Signal"},{"key":"R33-20260618","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13046-024-02979-z","article-title":"LATS1\/2 loss promote tumor immune evasion in endometrial cancer through downregulating MHC-I expression","volume":"43","author":"Yang","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"R34-20260618","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13249","article-title":"Single-cell sequencing reveals the heterogeneity and intratumoral crosstalk in human endometrial cancer","volume":"55","author":"Yu","year":"2022","journal-title":"Cell Prolif"},{"key":"R35-20260618","article-title":"Tumor derived extracellular vesicles drive T cell exhaustion in tumor microenvironment through sphingosine mediated signaling and impacting immunotherapy outcomes in ovarian cancer","volume":"9","author":"Gupta","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"R36-20260618","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1158\/0008-5472.CAN-20-0788","article-title":"Plasma gelsolin inhibits CD8+ T-cell function and regulates glutathione production to confer chemoresistance in ovarian cancer","volume":"80","author":"Asare-Werehene","year":"2020","journal-title":"Cancer Res"},{"key":"R37-20260618","article-title":"Bone marrow-resident Vdelta1 T cells co-express TIGIT with PD-1, TIM-3 or CD39 in AML and myeloma","volume":"8","author":"Brauneck","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R38-20260618","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/cac2.12486","article-title":"Interactions of Indoleamine 2,3-dioxygenase-expressing LAMP3+ dendritic cells with CD4+ regulatory T cells and CD8+ exhausted T cells: synergistically remodeling of the immunosuppressive microenvironment in cervical cancer and therapeutic implications","volume":"43","author":"Qu","year":"2023","journal-title":"Cancer Commun"},{"key":"R39-20260618","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"R40-20260618","article-title":"NAT10\/ac4C\/FOXP1 promotes malignant progression and facilitates immunosuppression by reprogramming glycolytic metabolism in cervical cancer","volume":"10","author":"Chen","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"R41-20260618","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2009.07.015","article-title":"Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma","volume":"115","author":"Inaba","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R42-20260618","article-title":"STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"R43-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005627","article-title":"STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer","volume":"11","author":"Ding","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R44-20260618","doi-asserted-by":"crossref","first-page":"217","DOI":"10.62347\/QTWJ8918","article-title":"Progress and prospects of the combination of BMI1-targeted therapy and immunotherapy in cervical cancer","volume":"15","author":"Chen","year":"2025","journal-title":"Am J Cancer Res"},{"key":"R45-20260618","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.7150\/thno.59605","article-title":"PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression","volume":"11","author":"Jiang","year":"2021","journal-title":"Theranostics"},{"key":"R46-20260618","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2024.04.022","article-title":"Trop-2 expression and the tumor immune microenvironment in cervical cancer","volume":"187","author":"Chiba","year":"2024","journal-title":"Gynecol Oncol"},{"key":"R47-20260618","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/vaccines4040036","article-title":"The role of myeloid-derived suppressor cells (MDSC) in cancer progression","volume":"4","author":"Umansky","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"R48-20260618","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00262-022-03226-0","article-title":"Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF\/BAFF-R pathway to promote immunosuppression in cervical cancer","volume":"72","author":"Jianyi","year":"2023","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"R49-20260618","first-page":"9507","article-title":"Circulating and tumor\u2011infiltrating myeloid\u2011derived suppressor cells in cervical carcinoma patients","volume":"15","author":"Wu","year":"2018","journal-title":"Oncol Lett"},{"key":"R50-20260618","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101272","article-title":"Ovarian cancer modulates the immunosuppressive function of CD11b+ Gr1+ myeloid cells via glutamine metabolism","volume":"53","author":"Udumula","year":"2021","journal-title":"Mol Metab"},{"key":"R51-20260618","article-title":"Myeloid-derived suppressor cells as therapeutic targets in uterine cervical and endometrial cancers","volume":"10","author":"Mabuchi","year":"2021","journal-title":"Cells"},{"key":"R52-20260618","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241279514","article-title":"Retinoids: Molecular aspects and treatment in premalignant lesions and cervical cancer","author":"Cort\u00e9s-Malag\u00f3n","year":"2024","journal-title":"Cancer Control"},{"key":"R53-20260618","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fonc.2019.00421","article-title":"Macrophage polarization in the development and progression of ovarian cancers: An overview","volume":"9","author":"Cheng","year":"2019","journal-title":"Front Oncol"},{"key":"R54-20260618","first-page":"1245","article-title":"The immune microenvironment of cancer of the uterine cervix","volume":"39","author":"Mastrogeorgiou","year":"2024","journal-title":"Histol Histopathol"},{"key":"R55-20260618","first-page":"443","article-title":"Role of tumor-associated macrophages in cervical cancer: Integrating classical perspectives with recent technological advances","volume":"14","author":"Choi","year":"2024","journal-title":"Life (Basel)"},{"key":"R56-20260618","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1219","article-title":"Spatiotemporally deciphering the mysterious mechanism of persistent HPV-induced malignant transition and immune remodelling from HPV-infected normal cervix, precancer to cervical cancer: Integrating single-cell RNA-sequencing and spatial transcriptome","volume":"13","author":"Guo","year":"2023","journal-title":"Clin Transl Med"},{"key":"R57-20260618","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/0008-5472.CAN-12-3542","article-title":"Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment","volume":"73","author":"Dijkgraaf","year":"2013","journal-title":"Cancer Res"},{"key":"R58-20260618","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009296","article-title":"CD14+macrophage-like cells as the linchpin of cervical cancer perpetrated immune suppression and early metastatic spread: A new therapeutic lead?","volume":"4","author":"Heeren","year":"2015","journal-title":"Oncoimmunology"},{"key":"R59-20260618","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","article-title":"Role of macrophage targeting in the antitumor activity of trabectedin","volume":"23","author":"Germano","year":"2013","journal-title":"Cancer Cell"},{"key":"R60-20260618","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41419-024-06522-y","article-title":"Single-cell RNA sequencing of cervical exfoliated cells reveals potential biomarkers and cellular pathogenesis in cervical carcinogenesis","volume":"15","author":"Sheng","year":"2024","journal-title":"Cell Death Dis"},{"key":"R61-20260618","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00011-022-01560-8","article-title":"Inflammatory profile in cervical cancer: influence of purinergic signaling and possible therapeutic targets","volume":"71","author":"Franciosi","year":"2022","journal-title":"Inflamm Res"},{"key":"R62-20260618","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10555-021-10002-6","article-title":"Adipocytokines and disease progression in endometrial cancer: a systematic review","volume":"41","author":"Ray","year":"2022","journal-title":"Cancer Metastasis Rev"},{"key":"R63-20260618","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood-2007-02-072587","article-title":"Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells","volume":"110","author":"Duluc","year":"2007","journal-title":"Blood"},{"key":"R64-20260618","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.1005693","article-title":"Cancer-associated fibroblasts in ovarian cancer: research progress","volume":"15","author":"Xu","year":"2025","journal-title":"Front Oncol"},{"key":"R65-20260618","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2017.03.002","article-title":"The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma","volume":"34","author":"Berti","year":"2017","journal-title":"Cytokine Growth Factor Rev"},{"key":"R66-20260618","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5114\/aoms.2017.71069","article-title":"Antisense of survivin inhibits cervical cancer growth in mice","volume":"15","author":"Xu","year":"2019","journal-title":"Arch Med Sci"},{"key":"R67-20260618","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1007\/s13277-015-4538-0","article-title":"Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients","volume":"37","author":"Wei","year":"2016","journal-title":"Tumor Biol"},{"key":"R68-20260618","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3390\/ijms20092183","article-title":"RANK-RANKL signaling in cancer of the uterine cervix: A review","volume":"20","author":"van Dam","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R69-20260618","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-023-01743-9","article-title":"TGF-\u03b2 signaling promotes cervical cancer metastasis via CDR1as","volume":"22","author":"Zhong","year":"2023","journal-title":"Mol Cancer"},{"key":"R70-20260618","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cytogfr.2024.10.006","article-title":"The role of transforming growth factor \u03b2 in cervical carcinogenesis","volume":"80","author":"Trugilo","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"key":"R71-20260618","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1158\/1078-0432.CCR-24-0385","article-title":"Cervical cancer evades the host immune system through the inhibition of type I interferon and CXCL9 by LIF","volume":"30","author":"Bonfill-Teixidor","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R72-20260618","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/path.1918","article-title":"The absence of expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2","volume":"208","author":"Zijlmans","year":"2006","journal-title":"J Pathol"},{"key":"R73-20260618","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.critrevonc.2018.10.011","article-title":"RANK\/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment","volume":"133","author":"van Dam","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"R74-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2372","article-title":"HPV testing as a screen for cervical cancer","volume":"350","author":"Goodman","year":"2015","journal-title":"BMJ"},{"key":"R75-20260618","first-page":"147","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer","volume":"62","author":"Saslow","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R76-20260618","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-21-0625","article-title":"Circulating HPV DNA as a marker for early detection of relapse in patients with cervical cancer","volume":"27","author":"Jeannot","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R77-20260618","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.23.00954","article-title":"Clinical validation of human papilloma virus circulating tumor DNA for early detection of residual disease after chemoradiation in cervical cancer","volume":"42","author":"Han","year":"2024","journal-title":"J Clin Oncol"},{"key":"R78-20260618","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/1878-0261.12709","article-title":"HPV-related methylation-based reclassification and risk stratification of cervical cancer","volume":"14","author":"Yang","year":"2020","journal-title":"Mol Oncol"},{"key":"R79-20260618","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1106757","article-title":"Cancer-associated fibroblasts in gynecological malignancies: are they really allies of the enemy?","volume":"13","author":"Villegas-Pineda","year":"2023","journal-title":"Front Oncol"},{"key":"R80-20260618","article-title":"Prognostic value of SOX9 in cervical cancer: Bioinformatics and experimental approaches","volume":"13","author":"Chen","year":"2022","journal-title":"Front Genetics"},{"key":"R81-20260618","article-title":"Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer","volume":"3","author":"Goode","year":"2017","journal-title":"JAMA Oncol"},{"key":"R82-20260618","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2009.03.022","article-title":"Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer","volume":"114","author":"de Jong","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R83-20260618","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R84-20260618","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ygyno.2024.04.001","article-title":"Adoptive T cell therapy for ovarian cancer","volume":"186","author":"Gitto","year":"2024","journal-title":"Gynecol Oncol"},{"key":"R85-20260618","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1158\/1078-0432.CCR-20-4394","article-title":"Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes coexpressing CD39, CD103, and PD-1 in ovarian cancer","volume":"27","author":"Laumont","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R86-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005443","article-title":"Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer","volume":"10","author":"Palomero","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R87-20260618","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canlet.2020.10.004","article-title":"APOBEC: A molecular driver in cervical cancer pathogenesis","volume":"496","author":"Revathidevi","year":"2021","journal-title":"Cancer Lett"},{"key":"R88-20260618","article-title":"Integrated bioinformatical analysis identifies GIMAP4 as an immune-related prognostic biomarker associated with remodeling in cervical cancer tumor microenvironment","volume":"9","author":"Xu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"R89-20260618","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00432-022-04465-5","article-title":"Diagnostic, prognostic, and immunological roles of CD177 in cervical cancer","volume":"149","author":"Liao","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"R90-20260618","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s43556-024-00196-w","article-title":"Effects of family regulator-mediated modification patterns and immunity characteristics on tumor-associated cell type in endometrial cancer","volume":"5","author":"Yang","year":"2024","journal-title":"Mol Biomed"},{"key":"R91-20260618","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2024.04.023","article-title":"Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer","volume":"187","author":"Jiang","year":"2024","journal-title":"Gynecol Oncol"},{"key":"R92-20260618","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/s41467-024-45974-w","article-title":"Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: A phase II clinical trial from the GINECO group","volume":"15","author":"Freyer","year":"2024","journal-title":"Nat Commun"},{"key":"R93-20260618","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1\u2013positive cervical cancer: Results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J Clin Oncol"},{"key":"R94-20260618","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.19.01021","article-title":"Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent\/persistent endometrial cancer","volume":"37","author":"Konstantinopoulos","year":"2019","journal-title":"J Clin Oncol"},{"key":"R95-20260618","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): An open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol"},{"key":"R96-20260618","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-cell\u2013inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J Clin Oncol"},{"key":"R97-20260618","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/jcm10020220","article-title":"Mutations in uterine cervix carcinoma","volume":"10","author":"Voutsadakis","year":"2021","journal-title":"J Clin Med"},{"key":"R98-20260618","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.2016.67.8722","article-title":"Clinicopathologic significance of mismatch repair defects in endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"34","author":"McMeekin","year":"2016","journal-title":"J Clin Oncol"},{"key":"R99-20260618","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e\u2013mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol"},{"key":"R100-20260618","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1158\/1078-0432.CCR-16-2655","article-title":"Immune microenvironment in microsatellite-instable endometrial cancers: Hereditary or sporadic origin matters","volume":"23","author":"Pakish","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R101-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009143","article-title":"Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer","volume":"12","author":"Grau Bejar","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R102-20260618","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"key":"R103-20260618","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1200\/jco.2015.33.15_suppl.5512","article-title":"Tumor infiltrating and peritumoral T cells and expression of PD-L1 in BRCA1\/2-mutated high grade serous ovarian cancers","volume":"33","author":"Strickland","year":"2015","journal-title":"J Clin Oncol"},{"key":"R104-20260618","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","article-title":"Ovarian cancer mutational processes drive site-specific immune evasion","volume":"612","author":"V\u00e1zquez-Garc\u00eda","year":"2022","journal-title":"Nature"},{"key":"R105-20260618","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/s43018-020-00139-8","article-title":"Mutations in and differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy","volume":"1","author":"Samstein","year":"2020","journal-title":"Nat Cancer"},{"key":"R106-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009058","article-title":"Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+ TILs based on BRCA1\/2 mutation status in epithelial ovarian cancers","volume":"12","author":"Park","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R107-20260618","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1186\/s40001-024-02191-x","article-title":"Cross-talk between cuproptosis and ferroptosis to identify immune landscape in cervical cancer for mRNA vaccines development","volume":"29","author":"Zhang","year":"2024","journal-title":"Eur J Med Res"},{"key":"R108-20260618","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"R109-20260618","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"R110-20260618","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I\/II CheckMate 358 trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J Clin Oncol"},{"key":"R111-20260618","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.annonc.2021.04.009","article-title":"VP4-2021: EMPOWER-cervical 1\/GOG-3016\/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator\u2019s choice (IC) chemotherapy (chemo) in recurrent\/metastatic (R\/M) cervical carcinoma","volume":"32","author":"Tewari","year":"2021","journal-title":"Ann Oncol"},{"key":"R112-20260618","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/CJI.0000000000000545","article-title":"Efficacy and safety of immune checkpoint inhibitors on advanced cervical cancer: A systematic review and meta-analysis","volume":"48","author":"Wang","year":"2025","journal-title":"J Immunother"},{"key":"R113-20260618","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(23)00531-4","article-title":"Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): A multicentre, single-arm, phase 2 trial","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"key":"R114-20260618","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: Final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"key":"R115-20260618","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"R116-20260618","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: Results from the KEYNOTE-158 study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J Clin Oncol"},{"key":"R117-20260618","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1\u2013positive endometrial cancer: Results from the KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"key":"R118-20260618","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti\u2013programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair\u2013deficient endometrial cancer: A nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol"},{"key":"R119-20260618","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ygyno.2024.05.025","article-title":"Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study","volume":"186","author":"Berton","year":"2024","journal-title":"Gynecol Oncol"},{"key":"R120-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002255","article-title":"Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial","volume":"9","author":"Antill","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R121-20260618","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol"},{"key":"R122-20260618","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"New Engl J Med"},{"key":"R123-20260618","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin\u2013paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann Oncol"},{"key":"R124-20260618","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"R125-20260618","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: Phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"R126-20260618","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: A phase 2 nonrandomized clinical trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol"},{"key":"R127-20260618","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti\u2013PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"key":"R128-20260618","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: A phase 2 clinical trial","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol"},{"key":"R129-20260618","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: Placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol"},{"key":"R130-20260618","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): An open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"R131-20260618","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2019.3857","article-title":"Sequential ipilimumab after chemoradiotherapy in curative-intent treatment of patients with node-positive cervical cancer","volume":"6","author":"Mayadev","year":"2020","journal-title":"JAMA Oncol"},{"key":"R132-20260618","doi-asserted-by":"crossref","first-page":"v898","DOI":"10.1093\/annonc\/mdz394.059","article-title":"LBA62 - Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent\/metastatic (R\/M) cervical cancer: Results from CheckMate 358","volume":"30","author":"Naumann","year":"2019","journal-title":"Ann Oncol"},{"key":"R133-20260618","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.medj.2024.02.003","article-title":"Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis","volume":"5","author":"Knisely","year":"2024","journal-title":"Med"},{"key":"R134-20260618","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.21.02067","article-title":"Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: An open-label phase II study","volume":"40","author":"O\u2019Malley","year":"2021","journal-title":"J Clin Oncol"},{"key":"R135-20260618","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/AOG.0000000000004573","article-title":"Complete response to combination nivolumab and ipilimumab in recurrent neuroendocrine carcinoma of the cervix","volume":"138","author":"Paterniti","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R136-20260618","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: An NRG oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J Clin Oncol"},{"key":"R137-20260618","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.2147\/DDDT.S374672","article-title":"Emerging therapeutic strategies of different immunotherapy approaches combined with PD-1\/PD-L1 blockade in cervical cancer","volume":"16","author":"Ge","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"R138-20260618","doi-asserted-by":"crossref","first-page":"10656","DOI":"10.1073\/pnas.1100354108","article-title":"HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes","volume":"108","author":"Gooden","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R139-20260618","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1158\/1078-0432.CCR-19-0298","article-title":"Dose-ranging and cohort-expansion study of monalizumab (IPH2201) in patients with advanced gynecologic malignancies: A trial of the canadian cancer trials group (CCTG): IND221","volume":"25","author":"Tinker","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R140-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007340","article-title":"Phase 1\/2 study of monalizumab plus durvalumab in patients with advanced solid tumors","volume":"12","author":"Patel","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R141-20260618","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/cncr.35063","article-title":"Phase 1\/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies","volume":"130","author":"Knisely","year":"2024","journal-title":"Cancer"},{"key":"R142-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009416","article-title":"Targeting CDCP1 boost CD8+T cells-mediated cytotoxicity in cervical cancer via the JAK\/STAT signaling pathway","volume":"12","author":"Huang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R143-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003667","article-title":"Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+TIL function in cervical cancer","volume":"10","author":"Wang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R144-20260618","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2024-009024","article-title":"Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer","volume":"12","author":"Wang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R145-20260618","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"R146-20260618","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1200\/JCO.22.01618","article-title":"Adoptive cell therapy for nonhematologic solid tumors","volume":"41","author":"Olson","year":"2023","journal-title":"J Clin Oncol"},{"key":"R147-20260618","article-title":"T cell immunotherapy for cervical cancer: challenges and opportunities","volume":"14","author":"Yu","year":"2023","journal-title":"Front Immunol"},{"key":"R148-20260618","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1200\/JCO.2014.60.6566","article-title":"Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer","volume":"33","author":"Zsiros","year":"2015","journal-title":"J Clin Oncol"},{"key":"R149-20260618","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/2159-8290.CD-NB2014-090","article-title":"T-cell therapy for cervical cancer","volume":"4","year":"2014","journal-title":"Cancer Discov"},{"key":"R150-20260618","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovic","year":"2015","journal-title":"J Clin Oncol"},{"key":"R151-20260618","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157726","article-title":"Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer","volume":"132","author":"Huang","year":"2022","journal-title":"J Clin Invest"},{"key":"R152-20260618","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2019.37.15_suppl.2538","article-title":"Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma","volume":"37","author":"Jazaeri","year":"2019","journal-title":"J Clin Oncol"},{"key":"R153-20260618","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1186\/s12967-023-04444-5","article-title":"Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient\u2019s response to conventional and novel therapies","volume":"21","author":"Liu","year":"2023","journal-title":"J Transl Med"},{"key":"R154-20260618","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","article-title":"The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy","volume":"20","author":"Mensurado","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"R155-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006822","article-title":"Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma","volume":"12","author":"Amaria","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R156-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007697","article-title":"Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer","volume":"11","author":"Verdegaal","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R157-20260618","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","article-title":"Engineered T cell therapy for viral and non-viral epithelial cancers","volume":"41","author":"Norberg","year":"2023","journal-title":"Cancer Cell"},{"key":"R158-20260618","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-023-01844-5","article-title":"The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells","volume":"22","author":"Li","year":"2023","journal-title":"Mol Cancer"},{"key":"R159-20260618","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99488","article-title":"Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model","volume":"3","author":"Jin","year":"2018","journal-title":"JCI Insight"},{"key":"R160-20260618","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"key":"R161-20260618","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/s41467-024-46558-4","article-title":"HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice","volume":"15","author":"Long","year":"2024","journal-title":"Nat Commun"},{"key":"R162-20260618","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-cell receptor gene therapy for human papillomavirus\u2013associated epithelial cancers: A first-in-human, phase I\/II study","volume":"37","author":"Doran","year":"2019","journal-title":"J Clin Oncol"},{"key":"R163-20260618","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"key":"R164-20260618","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Ann Rev Med"},{"key":"R165-20260618","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-018-0759-3","article-title":"Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer"},{"key":"R166-20260618","doi-asserted-by":"crossref","first-page":"718","DOI":"10.7150\/ijbs.14405","article-title":"New strategies for the treatment of solid tumors with CAR-T cells","volume":"12","author":"Zhang","year":"2016","journal-title":"Int J Biol Sci"},{"key":"R167-20260618","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.omtm.2020.06.022","article-title":"Ready for repair? Gene editing enters the clinic for the treatment of human disease","volume":"18","author":"Ernst","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"R168-20260618","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110562","article-title":"Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer","volume":"131","author":"Zhang","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"R169-20260618","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3390\/biom12091296","article-title":"Generation and functional characterization of PLAP CAR-T cells against cervical cancer cells","volume":"12","author":"Yekehfallah","year":"2022","journal-title":"Biomolecules"},{"key":"R170-20260618","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1362904","article-title":"Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model","volume":"15","author":"Soltantoyeh","year":"2024","journal-title":"Front Immunol"},{"key":"R171-20260618","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00262-022-03238-w","article-title":"Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"R172-20260618","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J Transl Med"},{"key":"R173-20260618","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13073-024-01405-5","article-title":"Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study","volume":"16","author":"Xu","year":"2024","journal-title":"Genome Med"},{"key":"R174-20260618","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1158\/0008-5472.CAN-20-2701","article-title":"Mesothelin-specific CAR T cells target ovarian cancer","volume":"81","author":"Schoutrop","year":"2021","journal-title":"Cancer Res"},{"key":"R175-20260618","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1007\/s00262-023-03529-w","article-title":"Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1","volume":"72","author":"Mun","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"R176-20260618","article-title":"The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"R177-20260618","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11864-021-00918-0","article-title":"The use of targeted agents in the treatment of gynecologic cancers","volume":"23","author":"Bruce","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"R178-20260618","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.21037\/tcr-24-272","article-title":"A retrospective study of anlotinib in patients with persistent, recurrent or metastatic cervical and endometrial cancer","volume":"13","author":"Xin","year":"2024","journal-title":"Transl Cancer Res"},{"key":"R179-20260618","doi-asserted-by":"crossref","first-page":"S640","DOI":"10.1016\/j.annonc.2020.08.1004","article-title":"865P a phase II study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent, or metastatic cervical cancer (CC)","volume":"31","author":"Xu","year":"2020","journal-title":"Ann Oncol"},{"key":"R180-20260618","doi-asserted-by":"crossref","first-page":"7581","DOI":"10.1038\/s41467-022-35133-4","article-title":"A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma","volume":"13","author":"Xia","year":"2022","journal-title":"Nat Commun"},{"key":"R181-20260618","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.20.01920","article-title":"Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): A multicenter, open-label, single-arm, phase II trial","volume":"38","author":"Lan","year":"2020","journal-title":"J Clin Oncol"},{"key":"R182-20260618","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202411454","article-title":"An oral PROTAC targeting HPK1 degradation potentiates anti-solid tumor immunity","volume":"37","author":"Yao","year":"2025","journal-title":"Adv Mater"},{"key":"R183-20260618","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature12881","article-title":"Landscape of genomic alterations in cervical carcinomas","volume":"506","author":"Ojesina","year":"2014","journal-title":"Nature"},{"key":"R184-20260618","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1186\/s12885-024-13226-1","article-title":"Real-world evidence of trastuzumab deruxtecan (T-DXd) efficacy in HER2-expressing gynecological malignancies","volume":"24","author":"Andrikopoulou","year":"2024","journal-title":"BMC Cancer"},{"key":"R185-20260618","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J Clin Oncol"},{"key":"R186-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004233","article-title":"Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer","volume":"10","author":"Lheureux","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R187-20260618","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial","volume":"42","author":"Westin","year":"2023","journal-title":"J Clin Oncol"},{"key":"R188-20260618","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaoncol.2022.2181","article-title":"Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer","volume":"8","author":"Konstantinopoulos","year":"2022","journal-title":"JAMA Oncol"},{"key":"R189-20260618","first-page":"A212","article-title":"348 A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12\/NOGGO)","volume":"8","author":"Slomovitz","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R190-20260618","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102790","article-title":"Locally advanced and metastatic endometrial cancer: Current and emerging therapies","volume":"129","author":"Salmon","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"R191-20260618","doi-asserted-by":"crossref","first-page":"viii334","DOI":"10.1093\/annonc\/mdy285.145","article-title":"936PD - A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)","volume":"29","author":"Lee","year":"2018","journal-title":"Ann Oncol"},{"key":"R192-20260618","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1158\/1078-0432.CCR-24-3877","article-title":"Comparing durvalumab, olaparib, and cediranib monotherapy, combination therapy, or chemotherapy in patients with platinum-resistant ovarian cancer with prior bevacizumab: The phase II NRG-GY023 trial","volume":"31","author":"Lee","year":"2025","journal-title":"Clin Cancer Res"},{"key":"R193-20260618","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2018.36.15_suppl.106","article-title":"TOPACIO\/Keynote-162 (NCT02657889): A phase 1\/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)\u2014Results from ROC cohort","volume":"36","author":"Konstantinopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"R194-20260618","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncology"},{"key":"R195-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003831","article-title":"Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study","volume":"10","author":"Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R196-20260618","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/vaccines13010092","article-title":"Advancing the fight against cervical cancer: The promise of therapeutic HPV vaccines","volume":"13","author":"Zheng","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"R197-20260618","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: A randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"R198-20260618","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-19-1513","article-title":"A phase II, prospective, randomized, multicenter, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3","volume":"26","author":"Choi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R199-20260618","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijrobp.2020.02.031","article-title":"A phase 1 trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6\/E7 oncogenes after chemoradiation for cervical cancer","volume":"107","author":"Hasan","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R200-20260618","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0706","article-title":"Human papillomavirus T-cell cross-reactivity in cervical cancer implications for immunotherapy clinical trial design","volume":"1","author":"Helman","year":"2018","journal-title":"JAMA Netw Open"},{"key":"R201-20260618","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/1078-0432.CCR-03-0056","article-title":"Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib\/II)","volume":"10","author":"Reinartz","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R202-20260618","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1158\/1078-0432.CCR-05-2670","article-title":"Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer","volume":"12","author":"Sabbatini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R203-20260618","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2012.46.4057","article-title":"Abagovomab As maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO\u2014The MIMOSA study","volume":"31","author":"Sabbatini","year":"2013","journal-title":"J Clin Oncol"},{"key":"R204-20260618","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","article-title":"Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer","volume":"27","author":"Berek","year":"2009","journal-title":"J Clin Oncol"},{"key":"R205-20260618","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2005.02.5973","article-title":"Phase III trial of intraperitoneal therapy with yttrium-90\u2013labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission","volume":"24","author":"Verheijen","year":"2006","journal-title":"J Clin Oncol"},{"key":"R206-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003190","article-title":"Safety and efficacy of dendritic cell-based immunotherapy DCVAC\/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: A phase 2, open-label, multicenter, randomized trial","volume":"10","author":"Rob","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R207-20260618","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1158\/1078-0432.CCR-21-4413","article-title":"An autologous dendritic cell vaccine promotes anticancer immunity in patients with ovarian cancer with low mutational burden and cold tumors","volume":"28","author":"Fucikova","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R208-20260618","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci Transl Med"},{"key":"R209-20260618","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1158\/1078-0432.CCR-17-2499","article-title":"Folate receptor alpha peptide vaccine generates immunity in breast and ovarian cancer patients","volume":"24","author":"Kalli","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R210-20260618","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1038\/s41467-020-18962-z","article-title":"Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients","volume":"11","author":"Block","year":"2020","journal-title":"Nat Commun"},{"key":"R211-20260618","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: Basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R212-20260618","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/2326-6066.CIR-14-0015","article-title":"Oncolytic viruses and their application to cancer immunotherapy","volume":"2","author":"Chiocca","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"R213-20260618","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3390\/cells12141838","article-title":"Developing oncolytic viruses for the treatment of cervical cancer","volume":"12","author":"Kalafati","year":"2023","journal-title":"Cells"},{"key":"R214-20260618","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/cr.2009.126","article-title":"VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis","volume":"20","author":"Xiao","year":"2010","journal-title":"Cell Res"},{"key":"R215-20260618","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ymthe.2005.06.443","article-title":"Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer","volume":"12","author":"Heideman","year":"2005","journal-title":"Mol Ther"},{"key":"R216-20260618","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12985-024-02502-y","article-title":"Oncolytic activity of a coxsackievirus B3 strain in patient-derived cervical squamous cell carcinoma organoids and synergistic effect with paclitaxel","volume":"21","author":"Lin","year":"2024","journal-title":"Virol J"},{"key":"R217-20260618","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/cgt.2011.53","article-title":"Oncolytic adenovirus armed with human papillomavirus E2 gene in combination with radiation demonstrates synergistic enhancements of antitumor efficacy","volume":"18","author":"Wang","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"R218-20260618","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.canlet.2009.09.022","article-title":"Selective targeting of HPV-16 E6\/E7 in cervical cancer cells with a potent oncolytic adenovirus and its enhanced effect with radiotherapy in vitro and vivo","volume":"291","author":"Wang","year":"2010","journal-title":"Cancer Lett"},{"key":"R219-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003645","article-title":"Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: A phase 1 clinical trial","volume":"9","author":"Moreno","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R220-20260618","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamaoncol.2023.1007","article-title":"Clinical activity of olvimulogene nanivacirepvec\u2013primed immunochemotherapy in heavily pretreated patients with platinum-resistant or platinum-refractory ovarian cancer: The nonrandomized phase 2 VIRO-15 clinical trial","volume":"9","author":"Holloway","year":"2023","journal-title":"JAMA Oncol"},{"key":"R221-20260618","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101056","article-title":"Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFN\u03b2 induces an anti-tumor immune response in high grade serous ovarian cancer","volume":"57","author":"Peters","year":"2024","journal-title":"Neoplasia"},{"key":"R222-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004335","article-title":"Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer","volume":"10","author":"van Vloten","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R223-20260618","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1016\/j.ymthe.2024.06.029","article-title":"Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine","volume":"32","author":"Basnet","year":"2024","journal-title":"Mol Ther"},{"key":"R224-20260618","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1158\/1078-0432.CCR-21-1248","article-title":"Targeting Fc receptor-mediated effects and the \u201cdon\u2019t eat me\u201d signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer","volume":"28","author":"Tian","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R225-20260618","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"R226-20260618","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"R227-20260618","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"R228-20260618","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): The STATICE trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J Clin Oncol"},{"key":"R229-20260618","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10585-014-9688-8","article-title":"T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2","volume":"32","author":"Nicoletti","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"R230-20260618","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"R231-20260618","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13046-015-0241-7","article-title":"Solitomab, an EpCAM\/CD3 bispecific antibody construct (BiTE\u00ae), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro","volume":"34","author":"Ferrari","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"R232-20260618","article-title":"A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE\u00ae) antibody construct, in patients with refractory solid tumors","volume":"7","author":"Kebenko","year":"2018","journal-title":"Oncoimmunology"},{"key":"R233-20260618","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1158\/1078-0432.CCR-23-3162","article-title":"Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): A phase 2 study","volume":"30","author":"Lou","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R234-20260618","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): A randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"key":"R235-20260618","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1158\/1078-0432.CCR-22-0346","article-title":"SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGFb, for recurrent or metastatic cervical cancer: A clinical expansion cohort of a phase I study","volume":"28","author":"Feng","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R236-20260618","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"R237-20260618","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1200\/JCO.2021.39.15_suppl.5504","article-title":"Mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis","volume":"39","author":"O\u2019Malley","year":"2021","journal-title":"J Clin Oncol"},{"key":"R238-20260618","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adh4379","article-title":"Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers","volume":"9","author":"Bordoloi","year":"2023","journal-title":"Sci Adv"},{"key":"R239-20260618","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/bjc.2014.443","article-title":"Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study","volume":"111","author":"Sehouli","year":"2014","journal-title":"Br J Cancer"},{"key":"R240-20260618","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","article-title":"Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM \u00d7 anti-CD3 antibody: A phase I\/II study","volume":"13","author":"Burges","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R241-20260618","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8345235","article-title":"TILs and Anti-PD1 therapy: An alternative combination therapy for PDL1 negative metastatic cervical cancer","volume":"2020","author":"Yin","year":"2020","journal-title":"J Immunol Res"},{"key":"R242-20260618","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s43018-023-00623-x","article-title":"A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer","volume":"4","author":"Bobisse","year":"2023","journal-title":"Nat Cancer"},{"key":"R243-20260618","article-title":"Autologous peripheral V\u03b39V\u03b42 T cell synergizes with \u03b1\u03b2 T cell through antigen presentation and BTN3A1 blockade in immunotherapy of cervical cancer","volume":"12","author":"Wu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"R244-20260618","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41392-023-01646-7","article-title":"Anti-PD-1 antibody armored \u03b3\u03b4 T cells enhance anti-tumor efficacy in ovarian cancer","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R245-20260618","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(20)30486-1","article-title":"Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial","volume":"21","author":"Youn","year":"2020","journal-title":"Lancet Oncol"},{"key":"R246-20260618","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16\u2013related cancer: A phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"key":"R247-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000829","article-title":"Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: A phase II trial","volume":"8","author":"Zamarin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R248-20260618","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12935-020-01476-5","article-title":"Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade","volume":"20","author":"Miri","year":"2020","journal-title":"Cancer Cell Int"},{"key":"R249-20260618","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002096","article-title":"Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis","volume":"9","author":"Gebremeskel","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R250-20260618","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ymthe.2003.08.004","article-title":"In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by e6 siRNA","volume":"8","author":"Yoshinouchi","year":"2003","journal-title":"Mol Ther"},{"key":"R251-20260618","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol"},{"key":"R252-20260618","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1158\/1078-0432.CCR-14-0250","article-title":"Zinc Finger nucleases targeting the human papillomavirus oncogene induce disruption and a transformed phenotype in HPV16\/18-Positive cervical cancer cells","volume":"20","author":"Ding","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R253-20260618","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1172\/JCI78206","article-title":"TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy","volume":"125","author":"Hu","year":"2014","journal-title":"J Clin Invest"},{"key":"R254-20260618","doi-asserted-by":"crossref","first-page":"11965","DOI":"10.1128\/JVI.01879-14","article-title":"Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR\/Cas RNA-guided endonuclease","volume":"88","author":"Kennedy","year":"2014","journal-title":"J Virology"},{"key":"R255-20260618","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jconrel.2023.07.007","article-title":"Genome editing mRNA nanotherapies inhibit cervical cancer progression and regulate the immunosuppressive microenvironment for adoptive T-cell therapy","volume":"360","author":"Ling","year":"2023","journal-title":"J Control Release"},{"key":"R256-20260618","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.omto.2021.12.011","article-title":"Gene knock-out chain reaction enables high disruption efficiency of HPV18 E6\/E7 genes in cervical cancer cells","volume":"24","author":"Tian","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"R257-20260618","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114041","article-title":"Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer","volume":"43","author":"Mishra","year":"2024","journal-title":"Cell Rep"},{"key":"R258-20260618","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ygyno.2020.07.025","article-title":"Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial","volume":"159","author":"Oaknin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R259-20260618","doi-asserted-by":"crossref","first-page":"22730","DOI":"10.1073\/pnas.1911385116","article-title":"Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy","volume":"116","author":"Zammataro","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R260-20260618","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","author":"Burk","year":"2017","journal-title":"Nature"},{"key":"R261-20260618","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cell.2020.01.026","article-title":"Proteogenomic characterization of endometrial carcinoma","volume":"180","author":"Dou","year":"2020","journal-title":"Cell"},{"key":"R262-20260618","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cell.2016.05.069","article-title":"Integrated proteogenomic characterization of human high-grade serous ovarian cancer","volume":"166","author":"Zhang","year":"2016","journal-title":"Cell"},{"key":"R263-20260618","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41588-023-01570-0","article-title":"Multiomic analysis of cervical squamous cell carcinoma identifies cellular ecosystems with biological and clinical relevance","volume":"55","author":"Fan","year":"2023","journal-title":"Nat Genet"},{"key":"R264-20260618","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1017\/erm.2024.30","article-title":"Adenosinergic signalling in cervical cancer microenvironment","volume":"27","author":"Iser","year":"2025","journal-title":"Expert Rev Mol Med"},{"key":"R265-20260618","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108198","article-title":"Patient-derived organoids as personalized avatars and a potential immunotherapy model in cervical cancer","volume":"26","author":"Huang","year":"2023","journal-title":"iScience"},{"key":"R266-20260618","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117553","article-title":"Advancements in nano-immunotherapy for gynecological cancers: A new frontier","volume":"180","author":"Gu","year":"2024","journal-title":"Biomed Pharmacother"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:00:44Z","timestamp":1781766044000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":266,"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000004166","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"2025-12-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}